PMID- 35864999
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220723
IS  - 1745-1981 (Print)
IS  - 1740-4398 (Electronic)
IS  - 1740-4398 (Linking)
VI  - 11
DP  - 2022
TI  - Prazosin for the management of behavioural and psychological symptoms of 
      dementia.
LID - 10.7573/dic.2022-3-3 [doi]
LID - 2022-3-3
AB  - Prazosin, a centrally acting alpha1 adrenoceptor antagonist, has been included in two 
      published algorithms amongst the list of medications that may be used in the 
      management of behavioural and psychological symptoms of dementia (BPSD). However, 
      a review of PubMed, Ovid and Cochrane Collaboration found that there was only one 
      small published randomized controlled trial (RCT) that evaluated the use of 
      prazosin amongst individuals with BPSD. Evidence from this good quality RCT 
      indicates that prazosin appears to benefit individuals with agitation and 
      aggression amongst individuals with BPSD and this medication is well tolerated. 
      When compared to other treatments for BPSD, including atypical antipsychotics, 
      antidepressants, acetylcholinesterase inhibitors, memantine, repetitive 
      transcranial magnetic stimulation and electroconvulsive therapy, where there are 
      multiple studies for each of these treatment modalities, the data for the use of 
      prazosin for BPSD are limited to just one good quality RCT. Given the limitations 
      in available data, the routine use of prazosin for the treatment of BPSD cannot 
      be recommended at this time. However, prazosin may be used for the management of 
      agitation and aggression amongst individuals with dementia when other medication 
      classes, like acetylcholinesterase inhibitors, memantine, antidepressants and/or 
      atypical antipsychotics, have been ineffective or not tolerated.
CI  - Copyright (c) 2022 Tampi RR, Tampi DJ, Farheen SA, Adnan M, Dasarathy D.
FAU - Tampi, Rajesh R
AU  - Tampi RR
AD  - Department of Psychiatry, Creighton University School of Medicine, Omaha, NE, 
      USA.
AD  - Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
FAU - Tampi, Deena J
AU  - Tampi DJ
AD  - Co-Founder and Managing Principal, Behavioral Health Advisory Group, Princeton, 
      NJ, USA.
FAU - Farheen, Syeda Arshiya
AU  - Farheen SA
AD  - Department of Psychiatry & Behavioral Sciences, Cleveland Clinic Akron General, 
      Akron, OH, USA.
FAU - Adnan, Mahwish
AU  - Adnan M
AD  - University of Toronto, Toronto, ON, Canada.
FAU - Dasarathy, Dhweeja
AU  - Dasarathy D
AD  - Vanderbilt University School of Medicine, Nashville, TN, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220701
PL  - England
TA  - Drugs Context
JT  - Drugs in context
JID - 101262187
PMC - PMC9267162
OTO - NOTNLM
OT  - aggression
OT  - agitation
OT  - behavioural and psychological symptoms of dementia
OT  - prazosin
OT  - randomized controlled trial
COIS- Disclosure and potential conflicts of interest: The authors declare that they 
      have no conflicts of interest relevant to this manuscript. The International 
      Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests 
      form for the authors is available for download at: 
      https://www.drugsincontext.com/wp-content/uploads/2022/06/dic.2022-3-3-COI.pdf
EDAT- 2022/07/23 06:00
MHDA- 2022/07/23 06:01
PMCR- 2022/07/01
CRDT- 2022/07/22 02:18
PHST- 2022/03/10 00:00 [received]
PHST- 2022/06/02 00:00 [accepted]
PHST- 2022/07/22 02:18 [entrez]
PHST- 2022/07/23 06:00 [pubmed]
PHST- 2022/07/23 06:01 [medline]
PHST- 2022/07/01 00:00 [pmc-release]
AID - dic-2022-3-3 [pii]
AID - 10.7573/dic.2022-3-3 [doi]
PST - epublish
SO  - Drugs Context. 2022 Jul 1;11:2022-3-3. doi: 10.7573/dic.2022-3-3. eCollection 
      2022.